¼¼°è ¼Ò¾Æ¿ë Ä«Å×ÅÍ ½ÃÀåÀº Ä«Å×ÅÍ ¼³°èÀÇ Çõ½Å, ÃÖ¼Òħ½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÇ·áºñ ÁöÃâ Áõ°¡, ¼Ò¾Æ ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µîÀ» ¹è°æÀ¸·Î 2024-2032³â ¿¬Æò±Õ 7.1%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿ä·Î°¨¿°Áõ(UTI), ¹æ±¤¿ä°ü ¿ª·ùÁõ(VUR), ½Å°æÀμº ¹æ±¤±â´ÉÀå¾Ö µî ¼Ò¾Æ ºñ´¢±â ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¼Ò¾Æ¿ë Ä«Å×ÅÍ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù.
BMC Infectious Diseases¿¡ µû¸£¸é ¿ä·Î°á¼®Àº ¼¼°è¿¡¼ µÎ ¹øÂ°·Î ÈçÇÑ °¨¿°¼º ÁúȯÀ¸·Î ¸Å³â 1¾ï 5,000¸¸ ¸í ÀÌ»ó¿¡°Ô ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¿ä·Î ¼¼±Õ °¨¿°ÀÌ Æ¯Â¡ÀÎ ¿ä·Î°á¼®Àº ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇØ ½Å¼ÓÇÑ Áø´Ü°ú Ä¡·á°¡ ÇÊ¿äÇϸç, ¼Òº¯ »ùÇÃÀ» äÃëÇϰí Åõ¾àÇϱâ À§ÇØ Ä«Å×Å͸¦ »ðÀÔÇÏ´Â °ÍÀÌ ÀϹÝÀûÀÔ´Ï´Ù.
¶ÇÇÑ, ½Å°æÇÐÀû Áõ»óÀ¸·Î ÀÎÇÑ ½Å°æÀμº ¹æ±¤ ±â´É Àå¾ÖÀÇ °æ¿ì, ¿äÆó ¹× °ü·Ã ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇØ Á¤±âÀûÀÎ Ä«Å×ÅÍ »ðÀÔÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¼Ò¾Æ¿ë Ä«Å×ÅÍ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¼Ò¾Æ ºñ´¢±â°ú¿¡¼ È¿°úÀûÀÎ Áø´Ü ¹× Ä¡·á °³ÀÔ¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ½À» ¹Ý¿µÇϸç, Á¦Á¶¾÷üµéÀº ¼Ò¾Æ ȯÀÚÀÇ Æ¯¼öÇÑ ¿ä±¸ »çÇ×À» ÃæÁ·½Ã۱â À§ÇØ Ä«Å×ÅÍ ¼Ö·ç¼ÇÀ» Çõ½ÅÇÏ°í °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.
¼Ò¾Æ¿ë Ä«Å×ÅÍ ½ÃÀåÀº Á¦Ç° À¯Çü, Àç·á, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.
ºñ´¢±â°ú Ä«Å×ÅÍ´Â ´Ù¾çÇÑ ¼Ò¾Æ ºñ´¢±â°ú ÁúȯÀÇ Áø´Ü ¹× Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ±â ¶§¹®¿¡ 2024³âºÎÅÍ 2032³â±îÁö Å« ¼öÀÍÀ» ¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Æú¸® Ä«Å×ÅÍ, °£ÇæÀû Ä«Å×ÅÍ, ü¿Ü Ä«Å×ÅÍ¿Í °°Àº ºñ´¢±â°ú Ä«Å×ÅÍ´Â ¼Ò¾Æ ȯÀÚÀÇ ¿äÆó, ¿ä½Ç±Ý ¹× ¹æ±¤ ±â´É Àå¾Ö¸¦ °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Ä£¼ö¼º ÄÚÆÃ, Ç×±Õ Æ¯¼º, ¼Ò¾Æ Àü¿ë »çÀÌÁî µî ºñ´¢±â°ú Ä«Å×ÅÍ ¼³°èÀÇ ²÷ÀÓ¾ø´Â ±â¼ú Çõ½ÅÀº ºñ´¢±â°ú¿ë Ä«Å×ÅÍÀÇ Ãß°¡ È®ÀåÀ» À§ÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
¿Ü·¡ ¼ö¼ú ¼¾ÅÍ(ASC) ºÐ¾ß´Â ¿Ü·¡ ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö°í ºñ¿ë È¿À²ÀûÀÎ ÀÇ·á Á¦°ø ¸ðµ¨¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ 2032³â±îÁö ¼Ò¾Æ¿ë Ä«Å×ÅÍ ½ÃÀå Á¡À¯À²À» Àû´çÈ÷ È®º¸ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ASC´Â ¼Ò¾Æ¿ë Ä«Å×ÅÍ Ä¡·á¸¦ À§ÇÑ Æí¸®Çϰí È¿À²ÀûÀΠȯ°æÀ» Á¦°øÇϰí, Àû½Ã °³ÀÔ, ÀÔ¿ø ±â°£ ´ÜÃà, ȯÀÚ ¸¸Á·µµ Çâ»óÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ, ASC ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ¿Ü·¡ Áø·á¼Ò ³×Æ®¿öÅ© È®´ë°¡ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼Ò¾Æ¿ë Ä«Å×ÅÍ ½ÃÀåÀº ±Þ¼ÓÇÑ µµ½ÃÈ, ÀÇ·áºñ ÁöÃâ Áõ°¡, ±ÞÁõÇÏ´Â ¼Ò¾Æ Àα¸¿¡ ÈûÀÔ¾î 2032³â±îÁö ÀûÀýÇÑ Æò°¡¸¦ ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áß±¹, Àεµ, ÀϺ»°ú °°Àº ±¹°¡¿¡¼´Â ¼Ò¾Æ ÀÇ·á ÀÎÇÁ¶ó°¡ ºü¸£°Ô ¹ßÀüÇϰí ÀÖÀ¸¸ç, ¼Ò¾Æ ºñ´¢±â°ú ¿¹¹æÀû ¹× Ä¡·áÀû °³ÀÔ¿¡ ´ëÇÑ Á߿伺ÀÌ °Á¶µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼Ò¾Æ ÀÇ·á Á¢±Ù¼º ¹× ÀÇ·áºñ ºÎ´ãÀ» °³¼±Çϱâ À§ÇÑ Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·ÂÀº ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
Global Pediatric Catheters Market will grow at 7.1% CAGR during 2024-2032, driven by technological innovations in catheter design, growing demand for minimally invasive procedures, increasing healthcare expenditure, and rising awareness about pediatric healthcare.
The increasing prevalence of pediatric urological disorders, such as urinary tract infections (UTIs), vesicoureteral reflux (VUR), and neurogenic bladder dysfunction, is a significant driver of growth in the pediatric catheters market.
According to BMC Infectious Diseases, UTIs rank as the second most prevalent infectious disease worldwide, impacting over 150 million individuals annually. UTIs, characterized by bacterial infection in the urinary tract, necessitate prompt diagnosis and treatment to prevent complications, with catheterization commonly employed for urine sample collection and medication administration.
Similarly, neurogenic bladder dysfunction, resulting from neurological conditions, mandates regular catheterization to prevent urinary retention and associated complications. The rising demand for pediatric catheters reflects the increasing need for effective diagnostic and therapeutic interventions in pediatric urology, prompting manufacturers to innovate and develop tailored catheter solutions to meet the unique requirements of pediatric patients.
The Pediatric Catheters Market is classified based on product type, material, end-use, and region.
The urology catheters segment will amass appreciable gains over 2024-2032, owing to their widespread use in the diagnosis and treatment of various pediatric urological conditions. Urology catheters, including Foley catheters, intermittent catheters, and external catheters, play a vital role in managing urinary retention, incontinence, and bladder dysfunction in pediatric patients. The continuous innovation in urology catheter designs, such as hydrophilic coatings, antimicrobial properties, and pediatric-specific sizes, is further driving expansion.
Ambulatory surgical centers (ASCs) segment will capture a modest pediatric catheters market share by 2032, driven by the increasing preference for outpatient procedures and the growing focus on cost-effective healthcare delivery models. ASCs offer a convenient and efficient setting for pediatric catheterization procedures, enabling timely interventions, reduced hospital stays, and enhanced patient satisfaction. Moreover, the rising investments in ASC infrastructure and the expanding network of outpatient clinics are bolstering market growth.
Asia Pacific Pediatric Catheters Market will garner a decent valuation by 2032, fueled by rapid urbanization, increasing healthcare expenditure, and a burgeoning pediatric population. Countries such as China, India, and Japan are witnessing a surge in pediatric healthcare infrastructure development, coupled with a growing emphasis on preventive and therapeutic pediatric urology interventions. Moreover, favorable government initiatives aimed at improving pediatric healthcare access and affordability are further propelling market growth in the region.